Amendment No. 7 to Schedule 13D for Vor Biopharma Inc.

Reprogrammed Interchange LLC and Reid Hoffman filed Amendment No. 7 to Schedule 13D for Vor Biopharma Inc., reporting changes in their ownership of the company's common stock. The amendment details a series of open market transactions from October 10, 2025, through October 14, 2025, where Reprogrammed Interchange LLC sold shares, resulting in a decrease in their ownership by more than one percent. The total number of shares sold during this period was 96,657, with weighted average sale prices ranging from $30.3192 to $32.436 per share. The amendment also includes a comprehensive list of transactions over the past 60 days, reflecting a significant reduction in their holdings. The Reporting Persons now beneficially own 1,278,118 shares, representing 18.6% of the outstanding common stock. The filing emphasizes that the information provided supplements the previously filed Schedule 13D and its amendments, with all other information remaining unchanged.